Venlafaxine hydrochloride
Price | USD19.00 |
Packge | 1Kg/Bag |
- Min. Order:1Kg/Bag
- Supply Ability:30kg
- Time:2022-07-21
Product Details
- Product NameVenlafaxine hydrochloride
- CAS No.99300-78-4
- EINECS No.619-421-1
- MFC17H28ClNO2
- MW313.86
- Appearancepowderwhite
- Melting point 207-209°C
- storage temp. 2-8°C
Density | 1.394 g/cm3 |
---|---|
Boiling Point | 397.6ºC at 760 mmHg |
Melting Point | 207-209ºC |
Molecular Formula | C17H28ClNO2 |
Molecular Weight | 313.863 |
Flash Point | 194.2ºC |
Exact Mass | 313.180847 |
PSA | 32.70000 |
LogP | 3.83760 |
Storage condition | Store at RT |
Ulrica JiangTrade member
Hong Kong TianSheng new material trading Co., LTD.Website:https://www.tianshengjt.comWhatsapp:+86 17320697058Email:ulrica@hktiansheng.com
Company Profile Introduction
My name is Nancy, the export manager of Hong Kong Tiansheng New Material Trading Co., LTD. We specialize in the production and export of various chemical materials, pharmaceutical raw materials.
Recommended supplier
-
VIP1年
- Molsyns Research
- Venelafaxine Reference Standard 99300-78-4 98%
- Inquiry
- 2024-04-01
-
VIP0年
- Ebenezer Industries
- 99300-78-4 98%
- Inquiry
- 2024-03-30
-
VIP1年
- Amoli Organics Pvt Ltd
- Venlafaxine hydrochloride 99300-78-4 98%
- Inquiry
- 2024-03-20
-
VIP1年
- Sibram Pharmaceutical
- 99300-78-4 Venlafaxine hydrochloride 99%
- Inquiry
- 2024-03-16
-
VIP1年
- Srini Pharmaceuticals Pvt Ltd
- 99300-78-4 Venlafaxine hydrochloride 98%
- Inquiry
- 2024-03-04
-
VIP1年
- Cohance Lifesciences (Previously RA Chem Pharma Ltd)
- Venlafaxine hydrochloride 99300-78-4 98%
- Inquiry
- 2024-02-28
-
VIP1年
- Alfa Omega Pharma
- Venlafaxine hydrochloride 98%
- Inquiry
- 2024-02-17
-
VIP1年
- Atul Bioscience Ltd
- 99300-78-4 99%
- Inquiry
- 2024-02-05
-
VIP1年
- Ralington Pharma
- 99300-78-4 Venlafaxine hydrochloride 98%
- Inquiry
- 2024-02-05
-
VIP1年
- Besil Chem LLP
- Venlafaxine hydrochloride 98%
- Inquiry
- 2024-01-29
- Since:2021-08-12
- Address: UNIT 1307,BEVERLEY COMMERCIAL,CENTRE,87-105 CHATHAM ROAD,SOUTH TSIM SHA TSUI,KLN,HONG KONG
INQUIRY